Stereotaxis, Inc. Form 8K - July 14, 2005
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
July 8, 2005
| STEREOTAXIS, INC. |
|
| (Exact Name of Registrant as Specified in Its Charter) |
| Delaware |
|
| (State or Other Jurisdiction of Incorporation) |
| 000-50884 |
94-3120386 |
|
|
| (Commission File Number) |
(IRS Employer Identification No.) |
| 4041 Forest Park Avenue, St. Louis, Missouri |
63108 |
|
|
| (Address of Principal Executive Offices) |
(Zip Code) |
| (314) 615-6940 |
|
| (Registrant's Telephone Number, Including Area Code) |
| |
|
| (Former Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|_|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|_| Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|_|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|_|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a
Material Definitive Agreement.
Stereotaxis, Inc. (“Stereotaxis”)
announced today that it has resolved a patent licensing dispute with the
University of Virginia Patent Foundation (UVAPF). Stereotaxis and the UVAPF entered into an agreement that eliminates any
requirement for the Company to pay royalties on Stereotaxis products that address clinical applications in the cardiovascular,
peripheral vascular and certain other clinical fields. In exchange Stereotaxis has agreed to pay UVAPF a one-time cash settlement
payment of $3.65 million. This resolution, which was amicably reached, absolves Stereotaxis of any obligations for future royalty
payments in its primary areas of clinical focus. Stereotaxis had previously accrued royalties of 5% on sales of products that might
be covered by these patents, and this accrual will no longer be required. Stereotaxis will take a one-time charge of approximately
$2.9 million to reflect this settlement.
A
copy of the Settlement Agreement is filed as Exhibit 10.1 hereto and is incorporated by
reference herein. The description of the Settlement Agreement contained herein is
qualified in its entirety by the full texts of such exhibit.
| Item 2.03. |
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
SheetArrangement of a Registrant. |
See
Item 1.01 described above and incorporated herein
Item 9.01. Financial
Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 14, 2005 |
By: |
/s/ James M. Stolze
|
|
Name: |
James M. Stolze |
|
Title: |
Vice President and Chief Financial Officer |
EXHIBIT INDEX